We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Accuracy of Point-of-Care Tests for Syphilis Analyzed

By LabMedica International staff writers
Posted on 12 Mar 2013
Syphilis is on the rise worldwide and there is an urgent need for reliable and rapid screening, particularly for people who live in areas where access to health care is limited. More...


A major change in approach to syphilis testing has been called for which recommends replacing first-line laboratory tests with point-of-care tests (POC) tests globally, especially in resource-limited settings.

An international team, led by scientists at McGill University Health Center (Montreal, QC, Canada) has demonstrated that rapid POC tests for syphilis are as accurate as conventional laboratory tests. Currently, syphilis is screened using conventional laboratory-based tests that can take up to three weeks to deliver results. These tests require chemical agents, trained staff, and a continuous supply of electricity, which are not readily available in some parts of the world. Rapid and POC tests can be performed on a simple finger stick sample one patient at a time, and the results communicated to the patient within 20 minutes, saving time and helping doctors order confirmatory tests and rapidly flagging patients who need treatment.

The team identified 18 rapid and POC tests in global use in a meta-analysis. The vast majority were immunochromatographic strip (ICS) based assays with most tests being Determine (Abbott Diagnostics; Maidenhead, UK) at 29% (38/131); SD Biolines (Standard Diagnostics; Seoul, South Korea) at 18% (23/131); VisiTect (Omega Diagnostics; Alva, UK) at 16% (21/131); and Syphicheck (Qualpro; Goa, India) at 15% (19/131). In whole blood sample, using a Treponema pallidum (TP) specific reference standard, under the imperfect reference standard assumption, sensitivity and specificity estimates for Determine was 86.3% and 95.9%; for SD Bioline was 84.5% and 98.0%; for Syphicheck was 74.5% and 99.6%; and for VisiTect was 74.3% and 99.4%.

Nitika Pant Pai, MD, MPH, PhD, a lead author of the study said, “Our study has major worldwide implications for populations living in rural areas with limited access to healthcare. These tests offer the potential to expedite first line screening in settings where people have no access to a primary care physician or where laboratories take more than a week to deliver results." The study was published on February 26, 2013, in the journal Public Library of Science ONE.

Related Links:

McGill University Health Center
Abbott Diagnostics
Standard Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Clinical Informatics Platform
CLARION™
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.